<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04310033</url>
  </required_header>
  <id_info>
    <org_study_id>38RC19.420</org_study_id>
    <secondary_id>2019-A03307-40</secondary_id>
    <nct_id>NCT04310033</nct_id>
  </id_info>
  <brief_title>Impact of ICU on the Quality of Life in Cancer Patients</brief_title>
  <acronym>QdV-ONCOREA</acronym>
  <official_title>Impact of ICU on the Quality of Life and Oncological Care of Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational, prospective, monocentric, case-control study. Investigators aim to&#xD;
      compare the quality of life and oncological treatment strategy in cancer patients admitted or&#xD;
      not in ICU.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion of cancer patients (cases) at discharge of surgical, cardiovascular and thoracic&#xD;
      and medical ICU of the Grenoble Alpes University Hospital.&#xD;
&#xD;
      Cases will be matched with cancer patients identified in oncologist's consultation.&#xD;
&#xD;
      Inclusion of controls from oncologist consultations (2 controls for 1 case) For cases and&#xD;
      controls, medical data will be collected at inclusion, 3 and 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 24, 2020</start_date>
  <completion_date type="Actual">July 13, 2021</completion_date>
  <primary_completion_date type="Actual">July 13, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>quality of life questionary 36-item short form survey instrument (36-SF)</measure>
    <time_frame>3 months</time_frame>
    <description>score of 0 (poor quality of life) to 100 (very good quality of life)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>intensity of antitumoral treatment compared to standard treatment</measure>
    <time_frame>3 months</time_frame>
    <description>standard treatment vs adaptated treatment vs palliative care standard treatment was defined by the treatment recommended in the ESMO guidelines for each cancer (lung, colorectal, and head and neck cancer)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life questionary 36-item short form survey instrument (36-SF)</measure>
    <time_frame>6 months</time_frame>
    <description>score of 0 (poor quality of life) to 100 (very good quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intensity of antitumoral treatment compared to standard treatment</measure>
    <time_frame>6 months</time_frame>
    <description>standard treatment vs adaptated treatment vs palliative care standard treatment was defined by the treatment recommended in the ESMO guidelines for each cancer (lung, colorectal, and head and neck cancer)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECOG - Performance status</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>From 0 (fully active) to 5 (dead)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of Daily Living</measure>
    <time_frame>6 months</time_frame>
    <description>From 0 (dependent ) to 6 (autonomous)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Anxiety scale from 0 (no anxiety) to 21 (anxiety) Depression Scale from 0 (no depression) to 21 (depression)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>&gt; 18 years old&#xD;
Non-opposition of the patient or relatives&#xD;
Lung, head and neck or colorectal cancer&#xD;
Non scheduled ICU admission&#xD;
At least 24 hours of ICU stay&#xD;
Alive at ICU discharge&#xD;
Able to answer by phone to quality of life questionary</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Cancer patients not admitted in ICU, matched with the cases according to&#xD;
the type of primary cancer&#xD;
the presence or absence of oncogenic addiction&#xD;
the setting of anticancer treatment (curative/palliative)&#xD;
the line of anticancer treatment (none/L1/L2-L3/&gt;L3).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>Quality of life questionary: 36-Item Short Form Survey Instrument (36-SF) at 3 and 6 months from inclusion By phone</description>
    <arm_group_label>Cases</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Lung, head and neck or colorectal cancer admitted in ICU (cases) or not (controls)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt; 18 ans&#xD;
&#xD;
          -  Non-opposition of the patient or relatives&#xD;
&#xD;
          -  Lung, head and neck or colorectal cancer&#xD;
&#xD;
          -  Non scheduled ICU admission&#xD;
&#xD;
          -  At least 24 hours of ICU stay&#xD;
&#xD;
          -  Alive at ICU discharge&#xD;
&#xD;
          -  Able to answer by phone to quality of life questionary&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to answer by phone to quality of life questionary&#xD;
&#xD;
          -  Patient participating in another clinical study that could interfere with the results&#xD;
             of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chu Grenoble Alpes</name>
      <address>
        <city>Grenoble Cedex 9</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 20, 2020</study_first_submitted>
  <study_first_submitted_qc>March 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2020</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quality of life</keyword>
  <keyword>Oncological care</keyword>
  <keyword>intensive care unit</keyword>
  <keyword>solid tumor</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

